A promising approach using engineered bacteriophages to target Fusobacterium nucleatum, a bacteria linked to oral health issues and colorectal cancer, through Phage Display methodology for personalized treatments.
This innovative peptide solution is designed to competitively block adhesion of Fusobacterium nucleatum to the oral mucosa, preventing gum disease. It utilizes PRB3-derived peptides to interfere with bacterial binding, o...